Back to News
Market Impact: 0.2
GRAIL Reaches Analyst Target Price
Source: Nasdaq
Analyst EstimatesMarket Technicals & FlowsHealthcare & Biotech
GRAIL shares rose above the average 12-month analyst price target of $76.00, trading at $79.95 per share. The move signals positive recent price momentum but also raises the prospect that analysts could reassess valuation or increase their targets.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
GRAL0.20
More News
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- Philips Profitability Beats Expectations on Cost Cutting, Sales
- Reliance’s Record $19 Billion Surge Lifts Nifty, Keeps India Bulls in the Game
- Oil price falls amid hope of a breakthrough to end Iran war
- Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70
- Binance seeks to shore up confidence after record $6.3 billion heist